A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
- Status
- CompletedResults none
- Why it is watched
- non-weight indication: addiction
- Who it enrolls
- age 21 Years to 65 Years; no BMI minimum stated; conditions: Alcohol Use Disorder
- Interventions
- Mazdutide; Placebo
- Conditions
- Alcohol Use Disorder
- Phase and size
- Phase 2 · 308 participants
- Dates
- Start 2025-02-06
Primary completion 2026-03-19 - Sponsor
- Eli Lilly and Company (Industry)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Behaviors Associated with Alcohol Use Disorder (AUD) as Assessed by the Timeline Followback MethodBaseline, Week 28
02Eligibility
Who can take part
Inclusion Criteria: * Current AUD diagnosis as defined by Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria. Exclusion Criteria: * Have a history of significant active or unstable major depressive disorder, suicidal ideation, or other severe psychiatric disorder within the last 12 months. * Have initiated psychotherapy, changed the intensity of psychotherapy, or other nondrug therapies (for example, acupuncture or hypnosis) within 8 weeks prior to enrollment. * Have received any medication for AUD in the last 30 days including but not limited to, disulfiram, acamprosate, naltrexone, gabapentin, baclofen, or topiramate. * Other protocol-specific inclusion and exclusion criteria may apply.
03Change log
Registry changes
No changes recorded since the trial was added.